<DOCUMENT>
<TYPE>EX-10.231
<SEQUENCE>3
<FILENAME>a2104577zex-10_231.htm
<DESCRIPTION>EXHIBIT 10.23.1
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03WDC1176_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kx1177_exhibit_10.23.1"> </A>
<A NAME="toc_kx1177_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;10.23.1    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kx1177_amendment"> </A>
<A NAME="toc_kx1177_2"> </A>
<BR></FONT><FONT SIZE=2><B>AMENDMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This amendment, effective on the last date of signature modifies and amends the Co-Promotion Agreement dated effective November&nbsp;26, 1997 (the
"AGREEMENT"), by and between Abbott Laboratories through its Ross Products Division, ("ABBOTT") and MedImmune,&nbsp;Inc. ("MEDIMMUNE"). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kx1177_witnesseth"> </A>
<A NAME="toc_kx1177_3"> </A>
<BR></FONT><FONT SIZE=2><B>WITNESSETH    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, MEDIMMUNE and ABBOTT entered into a Co-Promotion Agreement dated effective November&nbsp;26, 1997 in order to co-promote the
PRODUCT in the TERRITORY; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
MEDIMMUNE and ABBOTT now desire to amend the AGREEMENT in order to provide special consideration for Synagis sales ("Amendment"); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW
THEREFORE, in consideration of the promises and of the mutual covenants and agreements herein set forth, the parties hereto agree as follows: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Unless
otherwise stated capitalized terms have the same meaning herein as ascribed to them by the AGREEMENT.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>The
term of this Amendment shall be for one RSV selling Season beginning on July&nbsp;1, 2000 through June&nbsp;30, 2001. Thereafter, the terms and conditions of the Agreement
shall again apply in all respects, without any affect from this Amendment.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>During
the term of this Amendment, the following reporting and payment compensation shall apply for the NET SALES of PRODUCT sold for use in the TERRITORY by MEDIMMUNE or its AFFILATES
as follows:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD><FONT SIZE=2>ABBOTT
shall pay to MEDIMMUNE (CONFIDENTIAL TREATMENT REQUESTED) in two equal payments as follows: (CONFIDENTIAL TREATMENT REQUESTED) on or before August&nbsp;1, 2000; and
(CONFIDENTIAL TREATMENT REQUESTED) on or before October&nbsp;10, 2000.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD><FONT SIZE=2>ABBOTT
shall receive the following payment on NET SALES of PRODUCT. </FONT></DD></DL>
</DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>% Royalty</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>Threshold</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Amendment and the AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter thereof and supersedes all prior agreements and
understandings in this respect. There shall be no amendments or modifications to this Amendment or the AGREEMENT, except by a written document which is signed by both parties. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2104577",CP="MEDIMMUNE, INC.",DN="2",CHK=822690,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KX1177A.;6',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the parties have each caused this Amendment to be signed and delivered by its duly authorized officer or representative as indicated below. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>MEDIMMUNE,&nbsp;INC.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>ABBOTT LABORATORIES<BR></FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MELVIN D. BOOTH</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Melvin D. Booth</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>JOY AMUNDSON</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Joy Amundson</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
President&nbsp;&amp; Chief Operating Officer</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
Senior Vice President Ross Products</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
July&nbsp;28, 2000</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
July&nbsp;31, 2000</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2104577",CP="MEDIMMUNE, INC.",DN="2",CHK=555535,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KX1177A.;6',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03WDC1176_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kx1177_1">Exhibit 10.23.1</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kx1177_2">AMENDMENT</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kx1177_3">WITNESSETH</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=YLEE,SEQ=,EFW="2104577",CP="MEDIMMUNE, INC.",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
